Kiromic stock pops on FDA filing to start trial of Deltacel for lung cancer
Grandbrothers/iStock Editorial via Getty Images
- Kiromic BioPharma (NASDAQ:KRBP) stock rose ~5% on Monday after company said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) to start a phase 1 of KB-GDT-01 (Deltacel), in combination with an anti-tumor therapy to treat non-small cell lung cancer (NSCLC).
- The company noted that Deltacel is an allogeneic, non-viral, non-engineered off-the-shelf Gamma Delta T-cell (GDT) therapy.
- "Submitting this IND brings us one step closer to beginning human clinical testing with this incredible science and providing a promising treatment option to the tens of thousands of patients living with non-small cell lung cancer," said Kiromic CEO Pietro Bersani.